Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1

Molecular and Cellular Endocrinology

Volumn 335, Issue 2, 2011, Pages 166-176

  Fröjdö, Sara ^a,b,c,d,e   Durand, Christine ^a,b,c,d,e   Molin, Laurent ^d,f   Carey, Andrew L ^g   El Osta, Assam ^g   Kingwell, Bronwyn A ^g   Febbraio, Mark A ^g   Solari, Florence ^d,f   Vidal, Hubert ^a,b,c,d,e   Pirola, Luciano ^a,b,c,d,e  

^a CarMeN   (France)

^b CEMAGREF   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f CNRS UMR5201   (France)

^g BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Aging; C. elegans; Insulin signaling; Resveratrol; Sirtuins

Indexed keywords

INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P85; RESVERATROL; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CAENORHABDITIS ELEGANS; CELL STRAIN HEK293; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INACTIVATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN TREATMENT; LIFESPAN; MUSCLE BIOPSY; MUSCLE CELL; MYOTUBE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ADULT; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; CASE-CONTROL STUDIES; CELL LINE; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LONGEVITY; MIDDLE AGED; MUSCLE FIBERS, SKELETAL; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951726016     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2011.01.008     Document Type: Article

References (49)

1. Ayyadevara S., Alla R., Thaden J.J., Shmookler Reis R.J. Remarkable longevity and stress resistance of nematode PI3K-null mutants. Aging Cell 2008, 7:13-22.
2. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
3. Berdichevsky A., Viswanathan M., Horvitz H.R., Guarente L. C. elegans SIR-2.1 interacts with 14-3-3 proteins to activate DAF-16 and extend life span. Cell 2006, 125:1165-1177.
4. Bordone L., Motta M.C., Picard F., Robinson A., Jhala U.S., Apfeld J., McDonagh T., Lemieux M., McBurney M., Szilvasi A., et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol. 2006, 4:e31.
5. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280:17187-17195.
6. Chaudhary N., Pfluger P.T. Metabolic benefits from Sirt1 and Sirt1 activators. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12:431-437.
7. Chaussade C., Pirola L., Bonnafous S., Blondeau F., Brenz-Verca S., Tronchere H., Portis F., Rusconi S., Payrastre B., Laporte J., et al. Expression of myotubularin by an adenoviral vector demonstrates its function as a phosphatidylinositol 3-phosphate [PtdIns(3)P] phosphatase in muscle cell lines: involvement of PtdIns(3)P in insulin-stimulated glucose transport. Mol. Endocrinol. 2003, 17:2448-2460.
8. Cozzone D., Frojdo S., Disse E., Debard C., Laville M., Pirola L., Vidal H. Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients. Diabetologia 2008, 51:512-521.
9. de Alvaro C., Teruel T., Hernandez R., Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J. Biol. Chem. 2004, 279:17070-17078.
10. de Kreutzenberg S.V., Ceolotto G., Papparella I., Bortoluzzi A., Semplicini A., Dalla Man C., Cobelli C., Fadini G.P., Avogaro A. Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 2010, 59:1006-1015.
11. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes 2006, 55:2392-2397.
12. Elliott P.J., Jirousek M. Sirtuins: novel targets for metabolic disease. Curr. Opin. Investig. Drugs 2008, 9:371-378.
13. Ford J., Ahmed S., Allison S., Jiang M., Milner J. JNK2-dependent regulation of SIRT1 protein stability. Cell Cycle 2008, 7:3091-3097.
14. Frescas D., Valenti L., Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J. Biol. Chem. 2005, 280:20589-20595.
15. Frojdo S., Cozzone D., Vidal H., Pirola L. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem. J. 2007, 406:511-518.
16. Gerhart-Hines Z., Rodgers J.T., Bare O., Lerin C., Kim S.H., Mostoslavsky R., Alt F.W., Wu Z., Puigserver P. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 2007, 26:1913-1923.
17. Harikumar K.B., Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7:1020-1035.
18. Holzenberger M., Kappeler L., De Magalhaes Filho C. IGF-1 signaling and aging. Exp. Gerontol. 2004, 39:1761-1764.
19. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
20. Kaeberlein M., McDonagh T., Heltweg B., Hixon J., Westman E.A., Caldwell S.D., Napper A., Curtis R., DiStefano P.S., Fields S., et al. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 2005, 280:17038-17045.
21. Khwaja A., Lehmann K., Marte B.M., Downward J. Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J. Biol. Chem. 1998, 273:18793-18801.
22. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
23. Lee J.H., Song M.Y., Song E.K., Kim E.K., Moon W.S., Han M.K., Park J.W., Kwon K.B., Park B.H. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009, 58:344-351.
24. Lee Y.H., Giraud J., Davis R.J., White M.F. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J. Biol. Chem. 2003, 278:2896-2902.
25. Li Y., Xu W., McBurney M.W., Longo V.D. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab. 2008, 8:38-48.
26. Liang F., Kume S., Koya D. SIRT1 and insulin resistance. Nat. Rev. Endocrinol. 2009, 19:19.
27. Mihaylova V.T., Borland C.Z., Manjarrez L., Stern M.J., Sun H. The PTEN tumor suppressor homolog in Caenorhabditis elegans regulates longevity and dauer formation in an insulin receptor-like signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:7427-7432.
28. Morino K., Petersen K.F., Dufour S., Befroy D., Frattini J., Shatzkes N., Neschen S., White M.F., Bilz S., Sono S., et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J. Clin. Invest. 2005, 115:3587-3593.
29. Nemoto S., Fergusson M.M., Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J. Biol. Chem. 2005, 280:16456-16460.
30. North B.J., Marshall B.L., Borra M.T., Denu J.M., Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell 2003, 11:437-444.
31. Ota H., Tokunaga E., Chang K., Hikasa M., Iijima K., Eto M., Kozaki K., Akishita M., Ouchi Y., Kaneki M. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006, 25:176-185.
32. Ozes O.N., Akca H., Mayo L.D., Gustin J.A., Maehama T., Dixon J.E., Donner D.B. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:4640-4645.
33. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., Garofalo R.S., Griffith D., Griffor M., Loulakis P., Pabst B., et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285:8340-8351.
34. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M.W., Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004, 429:771-776.
35. Pirola L., Bonnafous S., Johnston A.M., Chaussade C., Portis F., Van Obberghen E. Phosphoinositide 3-kinase-mediated reduction of insulin receptor substrate-1/2 protein expression via different mechanisms contributes to the insulin-induced desensitization of its signaling pathways in L6 muscle cells. J. Biol. Chem. 2003, 278:15641-15651.
36. Rodgers J.T., Lerin C., Gerhart-Hines Z., Puigserver P. Metabolic adaptations through the PGC-1alpha and SIRT1 pathways. FEBS Lett. 2008, 582:46-53.
37. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434:113-118.
38. Rogina B., Helfand S.L. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:15998-16003.
39. Solari F., Bourbon-Piffaut A., Masse I., Payrastre B., Chan A.M., Billaud M. The human tumour suppressor PTEN regulates longevity and dauer formation in Caenorhabditis elegans. Oncogene 2005, 24:20-27.
40. Solinas G., Naugler W., Galimi F., Lee M.S., Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16454-16459.
41. Sun C., Zhang F., Ge X., Yan T., Chen X., Shi X., Zhai Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 2007, 6:307-319.
42. Tatar M., Bartke A., Antebi A. The endocrine regulation of aging by insulin-like signals. Science 2003, 299:1346-1351.
43. Tissenbaum H.A., Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001, 410:227-230.
44. van der Horst A., Tertoolen L.G., de Vries-Smits L.M., Frye R.A., Medema R.H., Burgering B.M. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J. Biol. Chem. 2004, 279:28873-28879.
45. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
46. Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., Tatar M., Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430:686-689.
47. Yoshizaki T., Milne J.C., Imamura T., Schenk S., Sonoda N., Babendure J.L., Lu J.C., Smith J.J., Jirousek M.R., Olefsky J.M. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol. Cell. Biol. 2009, 29:1363-1374.
48. Zhang J. Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem. J. 2006, 397:519-527.
49. Zhang J. The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J. Biol. Chem. 2007, 282:34356-34364.